Continued as an existing backer in Electra Therapeutics' $183M Series C, co-led by Nextech and EQT Life Sciences.
OCT 22, 2025
Electra Therapeutics is pioneering a new class of precision medicines focused on Signal Regulatory Protein (SIRP)-directed therapies aimed at improving outcomes for patients with immune-mediated diseases and cancer
Electra Therapeutics is pioneering a new class of precision medicines focused on Signal Regulatory Protein (SIRP)-directed therapies aimed at improving outcomes for patients with immune-mediated diseases and cancer.